European Companies Search Engine
EU funding (€7,482,729): I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination … Hor1 May 2015 EU Research and Innovation programme "Horizon"
Overview
Text
I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly
The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted. Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.
Funded Companies:
| Company name | Funding amount |
| Agence Nationale de Sante Publique | €0.00 |
| €0.00 | |
| Assistance Publique Hopitaux de Paris | €90,000 |
| Centre Hospitalier Universitaire Montpellier | €60,000 |
| €25,000 | |
| €587,308 | |
| €4,058.64 | |
| Epiconcept | €1,647,873 |
| Epiconcept UK Ltd. | €0.00 |
| Folkehelseinstituttet | €120,344 |
| €325,015 | |
| Hospices Civils de Lyon | €80,723 |
| €217,500 | |
| INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE | €350,159 |
| €0.00 | |
| €324,589 | |
| €248,625 | |
| Istituto Superiore DI Sanita | €392,500 |
| €50,000 | |
| €182,336 | |
| Narodowy Instytut Zdrowia Publicznego Pzh - Panstwowy Instytut Badawczy | €242,500 |
| €236,250 | |
| €139,842 | |
| €182,515 | |
| €519,508 | |
| Sorbonne Universite | €142,500 |
| Statens Serum Institut | €510,490 |
| €173,007 | |
| €448,650 | |
| The Royal College of General Practitioners | €162,506 |
| The University of Edinburgh | €18,931.25 |
| Universite de Corse Pascal Paoli | €0.00 |
| University of Strathclyde | €0.00 |
Source: https://cordis.europa.eu/project/id/634446
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Agence Nationale de Sante Publique - EU funding (€7,482,729): I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
